4D pharma and MSD collaborate to study Keytruda and MRx-0518 combination in solid tumors June 7, 2018
ROR-1-targeting cirmtuzumab inhibits stemness signatures in phase I trial in CLL patients June 7, 2018
Dosing begins in phase II expansion portion of monotherapy trial of eFT-508 in non-GCB DLBCL June 7, 2018
RSS